Biogen Beats Q1 Profit Estimates as Leqembi Sales Start to Take Off
Biogen on Wednesday exceeded analyst profit estimates for the first quarter of 2024 as the biotech’s cost-cutting measures took hold and sales of its Alzheimer’s disease therapy Leqembi started to pick up.